Comparative Pharmacology

Head-to-head clinical analysis: TRAVASOL 4 25 IN DEXTROSE 25 IN PLASTIC CONTAINER versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

TRAVASOL 4.25% IN DEXTROSE 25% IN PLASTIC CONTAINER

Parenteral Nutrition Solution

Category C

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER

Parenteral Nutrition Solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

TRAVASOL 4.25% IN DEXTROSE 25% provides crystalline amino acids and dextrose for parenteral nutrition. Amino acids serve as substrates for protein synthesis, while dextrose provides a carbohydrate source for energy. The formulation supplies essential and nonessential amino acids to maintain nitrogen balance and support tissue repair and growth.

TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% is a combination of amino acids, electrolytes, and dextrose used for parenteral nutrition. Amino acids provide substrates for protein synthesis; electrolytes maintain acid-base balance and cellular function; dextrose provides caloric energy. Sulfite-free formulation reduces risk of allergic reactions.

Clinical Dosing

Intravenous infusion; usual adult dose provides 0.5-2.0 g amino acids/kg/day, with dextrose providing 2-5 mg/kg/min; rate adjusted according to metabolic and fluid needs; typically infused over 24 hours via central line.

Intravenous infusion; dose determined by individual protein and caloric requirements, typically 1.5 to 2.5 g/kg/day of amino acids (equivalent to 35-59 mL/kg/day of TRAVASOL 4.25%) for adults.

Direct Interaction

None Documented